In recent years, the use of immune checkpoint inhibitors (ICIs), such as ipilimumab (the inhibitor of cytotoxic T‐lymphocyte antigen 4 [CTLA4]) and nivolumab (the inhibitor of programmed death‐1 [PD‐1]), have demonstrated survival benefits for HCC, which reveals that immune status is closely related to HCC progression.3, 4. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.